You are here:

MS in the media - 24 March 2016

Published on

19 - 24 March 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.

World Congress on Controversies in Neurology (CONy)

A meeting that took place in Lisbon from 17-20 March. Presentations included a number of debates on research topics

  • Vitamin D

A debate as to whether vitamin D can be considered disease modifying.

Source: MS News Today
MS Trust link: Vitamin D

  • MRI and disease modifying drugs

A debate around the role of MRI in managing disease modifying drugs in relapsing remitting MS

Source: MS News Today
MS Trust link: MS Decisions

  • Disease modifying drugs and biomarkers

Study looking at biomarkers in the blood to who would benefit from treatment with beta interferon

Source: MS News Today
MS Trust link: MS Decisions

  • Disease modifying drugs for secondary progressive MS

A debate about the value of disease modifying drugs once someone no longer has relapsing remitting MS

Source: MS News Today
MS Trust link: Secondary progressive MS

  • Remyelination

A debate on the value of remyelination treatments and whether promoting remyelination is proven to have long-term benefits

Source: MS News Today
MS Trust link: Remyelination

  • B vs T cells

A debate about whether to target T cells as well as B cells in treating MS. 

Source: MS News Today
MS Trust link: Immune system

  • PML

The pros and cons of treatments known to raise the risk of PML

Source: MS News Today
MS Trust link: PML

Proposed benefit changes withdrawn

Steven Crabb, the new Welfare and Pensions Secretary, has announced that the changes to PIP included in the budget won't be happening and that "as a government we are not seeking further savings from the welfare budget".

Source: BBC
Source: Guardian
Source: Daily Telegraph

MS Trust link: Benefits

Gadolinium safety review

The European Medicines Agency (EMA) has started a review of the safety of gadolinium deposits left in the body after MRI scans (for which it is used as a marker)

Source: EMA

MS Trust link: Gadolinium

Ibudilast fast track status

The company developing ibudilast as a potential treatment for progressive MS has announced that it will be classed as a "Fast Track Product" by the FDA, the US drug regulator.  This means quicker appraisal when the drug is submitted for licensing after phase III trials.  Ibudilast is currently being tested in a phase II trial that is due to complete in 2017.

Source: National MS Society

MS Trust link: Ibudilast

Print this page